What is the best treatment for pertussis?

Charles Tubbs, Heli Niemi, Helen G. Mayo

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

A 2005 Cochrane review of 11 RCTs and 1 quasi-randomized trial, with a total of 1720 adults and children, investigated several antibiotics for treatment and prophylaxis of pertussis. The outcome measures used to assess the efficacy of antibiotic treatment or prophylaxis vary between the trials and most of them did not report the immunization status of the participants. The Cochrane review included 1 meta-analysis of 3 studies with 252 participants, comparing azithromycin for 3 days, erythromycin estolate for 7 days, and clarithromycin for 7 days (short-term treatment) with erythromycin estolate for fourteen days (long-term treatment). The study showed equal efficacy in eradication of B pertussis from the nasopharynx of 99.2% to 97.7% (absolute risk reduction [ARR]=1.44%; 95% confidence interval [CI], -1.58 to 4.46). There were fewer side effects with the short-term treatment (32.1% vs 48.9%; ARR=16%; 95% CI, 7.84 to 25.84). A large, multicenter RCT of 477 children of 6 months to 16 years of age demonstrated that a 5-day treatment with azithromycin eradicated B pertussis from the nasopharynx as effectively as a 10-day course of erythromycin estolate. Similarly, trimethoprim/sulfamethoxazole proved as effective as erythromycin in eliminating B pertussis from the nasopharynx. Although tetracycline and chloramphenicol are effective treatments for pertussis, they are not recommended because of their side effects. Six randomized trials failed to show any statistically significant difference between antibiotics and placebo on frequency and severity of cough or duration of pertussis disease. A randomized, placebo-controlled trial studied 300 household contacts of children with culture-positive pertussis. There was no statistically significant difference in either the frequency of pertussis disease or rate of positive cultures in household contacts between the erythromycin group (2.1%) and the placebo group (5.1%) (ARR=2.95%; 95% CI, -1.21 to 7.11). Another Cochrane review of 8 trials examined the effectiveness of the symptomatic treatment of cough in children and adults with pertussis. There were many problems with the methodological quality of these trials, including small sample sizes and poor reporting of the methods. Diphenhydramine, pertussis immunoglobulin, corticosteroids and salbutamol were compared with placebo. There were no statistically significant differences in coughing paroxysms, mean number of whoops per 24 hours or in duration of hospital stay between these interventions and placebo. Extracorporeal circulatory life support has been used to maintain perfusion for patients with severe disease. The mortality of these patients is very high. No RCTs of the effectiveness of this intervention has been performed.

Original languageEnglish (US)
Pages (from-to)1096-1098
Number of pages3
JournalJournal of Family Practice
Volume54
Issue number12
StatePublished - Dec 1 2005

Fingerprint

Whooping Cough
Erythromycin Estolate
Numbers Needed To Treat
Placebos
Nasopharynx
Therapeutics
Azithromycin
Erythromycin
Confidence Intervals
Cough
Anti-Bacterial Agents
Diphenhydramine
Extracorporeal Membrane Oxygenation
Clarithromycin
Antibiotic Prophylaxis
Albuterol
Sulfamethoxazole Drug Combination Trimethoprim
Chloramphenicol
Tetracycline
Sample Size

ASJC Scopus subject areas

  • Family Practice

Cite this

What is the best treatment for pertussis? / Tubbs, Charles; Niemi, Heli; Mayo, Helen G.

In: Journal of Family Practice, Vol. 54, No. 12, 01.12.2005, p. 1096-1098.

Research output: Contribution to journalReview article

Tubbs, C, Niemi, H & Mayo, HG 2005, 'What is the best treatment for pertussis?', Journal of Family Practice, vol. 54, no. 12, pp. 1096-1098.
Tubbs, Charles ; Niemi, Heli ; Mayo, Helen G. / What is the best treatment for pertussis?. In: Journal of Family Practice. 2005 ; Vol. 54, No. 12. pp. 1096-1098.
@article{c7c66011a4d74aef9afcad460f92f6fd,
title = "What is the best treatment for pertussis?",
abstract = "A 2005 Cochrane review of 11 RCTs and 1 quasi-randomized trial, with a total of 1720 adults and children, investigated several antibiotics for treatment and prophylaxis of pertussis. The outcome measures used to assess the efficacy of antibiotic treatment or prophylaxis vary between the trials and most of them did not report the immunization status of the participants. The Cochrane review included 1 meta-analysis of 3 studies with 252 participants, comparing azithromycin for 3 days, erythromycin estolate for 7 days, and clarithromycin for 7 days (short-term treatment) with erythromycin estolate for fourteen days (long-term treatment). The study showed equal efficacy in eradication of B pertussis from the nasopharynx of 99.2{\%} to 97.7{\%} (absolute risk reduction [ARR]=1.44{\%}; 95{\%} confidence interval [CI], -1.58 to 4.46). There were fewer side effects with the short-term treatment (32.1{\%} vs 48.9{\%}; ARR=16{\%}; 95{\%} CI, 7.84 to 25.84). A large, multicenter RCT of 477 children of 6 months to 16 years of age demonstrated that a 5-day treatment with azithromycin eradicated B pertussis from the nasopharynx as effectively as a 10-day course of erythromycin estolate. Similarly, trimethoprim/sulfamethoxazole proved as effective as erythromycin in eliminating B pertussis from the nasopharynx. Although tetracycline and chloramphenicol are effective treatments for pertussis, they are not recommended because of their side effects. Six randomized trials failed to show any statistically significant difference between antibiotics and placebo on frequency and severity of cough or duration of pertussis disease. A randomized, placebo-controlled trial studied 300 household contacts of children with culture-positive pertussis. There was no statistically significant difference in either the frequency of pertussis disease or rate of positive cultures in household contacts between the erythromycin group (2.1{\%}) and the placebo group (5.1{\%}) (ARR=2.95{\%}; 95{\%} CI, -1.21 to 7.11). Another Cochrane review of 8 trials examined the effectiveness of the symptomatic treatment of cough in children and adults with pertussis. There were many problems with the methodological quality of these trials, including small sample sizes and poor reporting of the methods. Diphenhydramine, pertussis immunoglobulin, corticosteroids and salbutamol were compared with placebo. There were no statistically significant differences in coughing paroxysms, mean number of whoops per 24 hours or in duration of hospital stay between these interventions and placebo. Extracorporeal circulatory life support has been used to maintain perfusion for patients with severe disease. The mortality of these patients is very high. No RCTs of the effectiveness of this intervention has been performed.",
author = "Charles Tubbs and Heli Niemi and Mayo, {Helen G.}",
year = "2005",
month = "12",
day = "1",
language = "English (US)",
volume = "54",
pages = "1096--1098",
journal = "Journal of Family Practice",
issn = "0094-3509",
publisher = "Appleton-Century-Crofts",
number = "12",

}

TY - JOUR

T1 - What is the best treatment for pertussis?

AU - Tubbs, Charles

AU - Niemi, Heli

AU - Mayo, Helen G.

PY - 2005/12/1

Y1 - 2005/12/1

N2 - A 2005 Cochrane review of 11 RCTs and 1 quasi-randomized trial, with a total of 1720 adults and children, investigated several antibiotics for treatment and prophylaxis of pertussis. The outcome measures used to assess the efficacy of antibiotic treatment or prophylaxis vary between the trials and most of them did not report the immunization status of the participants. The Cochrane review included 1 meta-analysis of 3 studies with 252 participants, comparing azithromycin for 3 days, erythromycin estolate for 7 days, and clarithromycin for 7 days (short-term treatment) with erythromycin estolate for fourteen days (long-term treatment). The study showed equal efficacy in eradication of B pertussis from the nasopharynx of 99.2% to 97.7% (absolute risk reduction [ARR]=1.44%; 95% confidence interval [CI], -1.58 to 4.46). There were fewer side effects with the short-term treatment (32.1% vs 48.9%; ARR=16%; 95% CI, 7.84 to 25.84). A large, multicenter RCT of 477 children of 6 months to 16 years of age demonstrated that a 5-day treatment with azithromycin eradicated B pertussis from the nasopharynx as effectively as a 10-day course of erythromycin estolate. Similarly, trimethoprim/sulfamethoxazole proved as effective as erythromycin in eliminating B pertussis from the nasopharynx. Although tetracycline and chloramphenicol are effective treatments for pertussis, they are not recommended because of their side effects. Six randomized trials failed to show any statistically significant difference between antibiotics and placebo on frequency and severity of cough or duration of pertussis disease. A randomized, placebo-controlled trial studied 300 household contacts of children with culture-positive pertussis. There was no statistically significant difference in either the frequency of pertussis disease or rate of positive cultures in household contacts between the erythromycin group (2.1%) and the placebo group (5.1%) (ARR=2.95%; 95% CI, -1.21 to 7.11). Another Cochrane review of 8 trials examined the effectiveness of the symptomatic treatment of cough in children and adults with pertussis. There were many problems with the methodological quality of these trials, including small sample sizes and poor reporting of the methods. Diphenhydramine, pertussis immunoglobulin, corticosteroids and salbutamol were compared with placebo. There were no statistically significant differences in coughing paroxysms, mean number of whoops per 24 hours or in duration of hospital stay between these interventions and placebo. Extracorporeal circulatory life support has been used to maintain perfusion for patients with severe disease. The mortality of these patients is very high. No RCTs of the effectiveness of this intervention has been performed.

AB - A 2005 Cochrane review of 11 RCTs and 1 quasi-randomized trial, with a total of 1720 adults and children, investigated several antibiotics for treatment and prophylaxis of pertussis. The outcome measures used to assess the efficacy of antibiotic treatment or prophylaxis vary between the trials and most of them did not report the immunization status of the participants. The Cochrane review included 1 meta-analysis of 3 studies with 252 participants, comparing azithromycin for 3 days, erythromycin estolate for 7 days, and clarithromycin for 7 days (short-term treatment) with erythromycin estolate for fourteen days (long-term treatment). The study showed equal efficacy in eradication of B pertussis from the nasopharynx of 99.2% to 97.7% (absolute risk reduction [ARR]=1.44%; 95% confidence interval [CI], -1.58 to 4.46). There were fewer side effects with the short-term treatment (32.1% vs 48.9%; ARR=16%; 95% CI, 7.84 to 25.84). A large, multicenter RCT of 477 children of 6 months to 16 years of age demonstrated that a 5-day treatment with azithromycin eradicated B pertussis from the nasopharynx as effectively as a 10-day course of erythromycin estolate. Similarly, trimethoprim/sulfamethoxazole proved as effective as erythromycin in eliminating B pertussis from the nasopharynx. Although tetracycline and chloramphenicol are effective treatments for pertussis, they are not recommended because of their side effects. Six randomized trials failed to show any statistically significant difference between antibiotics and placebo on frequency and severity of cough or duration of pertussis disease. A randomized, placebo-controlled trial studied 300 household contacts of children with culture-positive pertussis. There was no statistically significant difference in either the frequency of pertussis disease or rate of positive cultures in household contacts between the erythromycin group (2.1%) and the placebo group (5.1%) (ARR=2.95%; 95% CI, -1.21 to 7.11). Another Cochrane review of 8 trials examined the effectiveness of the symptomatic treatment of cough in children and adults with pertussis. There were many problems with the methodological quality of these trials, including small sample sizes and poor reporting of the methods. Diphenhydramine, pertussis immunoglobulin, corticosteroids and salbutamol were compared with placebo. There were no statistically significant differences in coughing paroxysms, mean number of whoops per 24 hours or in duration of hospital stay between these interventions and placebo. Extracorporeal circulatory life support has been used to maintain perfusion for patients with severe disease. The mortality of these patients is very high. No RCTs of the effectiveness of this intervention has been performed.

UR - http://www.scopus.com/inward/record.url?scp=30944438881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30944438881&partnerID=8YFLogxK

M3 - Review article

C2 - 16321352

AN - SCOPUS:30944438881

VL - 54

SP - 1096

EP - 1098

JO - Journal of Family Practice

JF - Journal of Family Practice

SN - 0094-3509

IS - 12

ER -